Format

Send to

Choose Destination
Curr Probl Cancer. 2017 Jan - Feb;41(1):37-47. doi: 10.1016/j.currproblcancer.2016.11.002. Epub 2016 Nov 11.

Targeting fibroblast growth factor pathways in endometrial cancer.

Author information

1
Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, Minnesota.
2
Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. Electronic address: gkonecny@mednet.ucla.edu.

Abstract

Novel treatments that improve outcomes for patients with recurrent or metastatic endometrial cancer (EC) remain an unmet need. Aberrant signaling by fibroblast growth factors (FGFs) and FGF receptors (FGFRs) has been implicated in several human cancers. Activating mutations in FGFR2 have been found in up to 16% of ECs, suggesting an opportunity for targeted therapy. This review summarizes the role of the FGF pathway in angiogenesis and EC, and provides an overview of FGFR-targeted therapies under clinical development for the treatment of EC.

KEYWORDS:

Angiogenesis; Endometrial cancer; Fibroblast growth factor

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center